RxDoctor Payments Data

Alison Delich, APRN

Family · Overland Park, KSNPI 1265811442

Payments from drug & device makers

$3,583in general payments, 2019–2025

Across 256 payments — averaging $14.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$660
  • AstraZeneca$283
  • GSK$166
  • Biohaven Pharmaceutical Holding Company Ltd.$143
  • Corium, LLC$110
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,53399%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,583 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$26,666
Medicare patients
92
Services billed
1,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide42$43,910
OzempicSemaglutide41$42,874
JardianceEmpagliflozin42$42,115
EliquisApixaban45$34,223
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,573
Duloxetine Hcl39$1,652
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$1,358
Omeprazole60$1,333
Atorvastatin Calcium124$1,263
Gabapentin83$1,263
Albuterol Sulfate HfaAlbuterol Sulfate35$1,216
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$874
Rosuvastatin Calcium98$847
Losartan Potassium95$797
Levothyroxine Sodium104$782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$660$43,91042 claims
Novo NordiskOzempic$109$42,87441 claims
Boehringer IngelheimJardiance$64$42,11542 claims
PfizerEliquis$98$34,22345 claims
AstraZenecaBreztri Aerosphere$283$7,57312 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$32$782104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,579 family providers in Kansas.

Other family in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →